Outpoll | Outpoll Weekly Recap: Science (January 26

Science

The frontier of biology and computation blurred dramatically this week, with prediction markets surging on the back of a landmark CRISPR-Cas12b trial for Huntington's disease. Early data from Vertex Pharmaceuticals showed a staggering 60% reduction in mutant huntingtin protein in cerebrospinal fluid, sending the 'FDA approval by 2028' contract on Kalshi's science board soaring to a 78% probability—a 40-point week-on-week jump that left traditional analysts scrambling.This isn't just another incremental step; it's the kind of paradigm-shifting validation that rewrites the clinical playbook overnight, suggesting we're moving from treating symptoms to surgically excising genetic errors at their source. Meanwhile, in the realm of synthetic biology, Ginkgo Bioworks and Synlogic announced a partnership to engineer probiotics for metabolizing oxalate, a primary cause of kidney stones.The 'first human trial success' prediction rocketed to 65%, reflecting a growing market confidence in moving beyond single-gene edits to programming entire microbial consortia for in vivo therapeutic functions. This trend points to a future where our own microbiome becomes a programmable pharmacy, a vision that's rapidly transitioning from sci-fi to a heavily traded asset class.On the AI-for-science front, DeepMind's AlphaFold 3. 5 stunned the structural biology community by not only predicting protein-ligand interactions with unprecedented accuracy but also generating novel, stable protein scaffolds for carbon capture.The contract for 'AI-designed enzyme achieving industrial-scale CO2 fixation by 2027' saw a 22-point bump, signaling a bet that computational design is poised to leapfrog decades of slow, iterative lab work. The week's volatility, however, wasn't confined to biotech.A sharp, 30% correction hit contracts tied to the 'detection of technosignatures from Proxima Centauri b by 2030' following a sobering re-analysis of anomalous radio signals by the SETI Institute, attributed to terrestrial interference—a classic reminder that in the search for cosmic company, the noise often masquerades as the signal. Yet, the underlying bullish sentiment for astrobiology discovery remained resilient, simply shifting to more conservative timelines.The narrative this week is clear: we are witnessing the convergence of biological precision and computational brute force, creating a feedback loop where each successful experiment de-risks the next, more ambitious prediction. The markets are no longer just betting on papers; they're pricing in a near-future where genetic diseases are editable, microbes are therapeutic factories, and climate solutions are computationally grown. The science of the 2020s is being written in code—both genetic and digital—and the prediction markets are its first, most sensitive readers.

#Weekly recap

Outpoll Weekly Recap: Science (January 26 – February 1, 2026)